50 assets in Female Reproductive Organ Cancer

Therapeutic assets addressing Female Reproductive Organ Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Female Reproductive Organ Cancer	AbbVie	P2/3	BB (68)
Indocyanine Green Female Reproductive Organ Cancer	Istanbul University	P4	BB (65)
Atezolizumab Female Reproductive Organ Cancer	M.D. Anderson Cancer Center	P2	B (62)
Normal Human Serum Albumin Female Reproductive Organ Cancer	Joachim Zdolsek	P4	B (62)
Ringer'S Acetate Female Reproductive Organ Cancer	Joachim Zdolsek	P4	B (62)
Durvalumab Female Reproductive Organ Cancer	Institute of Cancer Research, United Kingdom	P2	B (60)
Fulvestrant Female Reproductive Organ Cancer	Atavistik Bio, Inc	P2	B (60)
Olaparib Female Reproductive Organ Cancer	AbbVie	P2	B (60)
Selumetinib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	B (60)
Dehydroepiandrosterone Female Reproductive Organ Cancer	Ohio State University Comprehensive Cancer Center	P3	B (59)
Cyclophosphamide Female Reproductive Organ Cancer	Mayo Clinic	P2	B (58)
Lenvatinib Female Reproductive Organ Cancer	Elizabeth K. Lee MD	P2	B (58)
Pembrolizumab Female Reproductive Organ Cancer	Elizabeth K. Lee MD	P2	B (58)
Nilotinib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	B (57)
Oxaliplatin Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	B (56)
Abemaciclib Female Reproductive Organ Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Alpelisib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Belzutifan Female Reproductive Organ Cancer	Dana-Farber Cancer Institute	P2	CCC (53)
Binimetinib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ceralasertib Female Reproductive Organ Cancer	Institute of Cancer Research, United Kingdom	P2	CCC (53)
Fluorouracilum Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Hydroxychloroquine Female Reproductive Organ Cancer	University of Arizona	P2	CCC (53)
Imgn151 Female Reproductive Organ Cancer	AbbVie	P2	CCC (53)
Ipatasertib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Neratinib Maleate Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Palbociclib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Panitumumab Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Riluzole Female Reproductive Organ Cancer	University of California, Irvine	P2	CCC (53)
Romiplostim Female Reproductive Organ Cancer	Peking University People's Hospital	P2	CCC (53)
Sotorasib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Tretinoin Female Reproductive Organ Cancer	Peking University People's Hospital	P2	CCC (53)
Pyruvate Female Reproductive Organ Cancer	Chang Gung Memorial Hospital	P2	CCC (49)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide Female Reproductive Organ Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P1/2	CCC (48)
Neoantigen Specific Tcr-T Cell Drug Product Female Reproductive Organ Cancer	Alaunos Therapeutics	P1/2	CC (45)
Atv-1601 Female Reproductive Organ Cancer	Atavistik Bio, Inc	P1	CC (43)
Autologous Muc1-Activated T-Cells Female Reproductive Organ Cancer	Mayo Clinic	P1	CC (43)
Bendamustine Female Reproductive Organ Cancer	Mayo Clinic	P1	CC (43)
Clostridium Novyi-Nt Female Reproductive Organ Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Doxycycline Female Reproductive Organ Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Talazoparib Female Reproductive Organ Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Brodalumab Female Reproductive Organ Cancer	Brian Henick, MD	P1	CC (41)
cd70-targeting car-t cells Female Reproductive Organ Cancer	Chongqing Precision Biotech Co., Ltd	P1	CC (41)
dk210 Female Reproductive Organ Cancer	DEKA Biosciences	P1	CC (41)
Dp Cd8 Til Female Reproductive Organ Cancer	AgonOx, Inc.	P1	CC (41)
Fludarabine Female Reproductive Organ Cancer	Masonic Cancer Center, University of Minnesota	P1	CC (41)
ft536 Female Reproductive Organ Cancer	Masonic Cancer Center, University of Minnesota	P1	CC (41)
R130 Female Reproductive Organ Cancer	Shanghai Yunying Medical Technology	Early P1	C (38)
Ferric Cation Female Reproductive Organ Cancer	Asan Medical Center	N/A	D (30)
Cabozantinib Female Reproductive Organ Cancer	M.D. Anderson Cancer Center	P1	NR ()
Cryptivax-1001 Female Reproductive Organ Cancer	Epitopea Ltd	P1	NR ()